Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
These results indicated that the more severe of OI, the lower LCN2 levels, and the more obvious metabolic disorder.Serum LCN2 levels with different clinical and genotypic classifications of OI children. a Serum LCN2 levels with different clinical severity of OI children. b Serum LCN2 levels with different genotypes of OI children. *P < 0.05Metabolic disorder in OI children with different clinical severityTotal OI patientsOI-type IOI-type IIIOI-type IVP value(n = 204)(n = 84)(n = 36)(n = 78)Male, n (%)151 (67.1%)64 (66.7%)a21 (58.3%)a,c62 (76.5%)c0.048Age (y)8.0 ± 4.78.8 ± 4.57.4 ± 4.67.9 ± 4.60.249Height (cm)119.6 ± 27.9128.3 ± 28.3a,b101.9 ± 24.9a,c119.5 ± 25.5b,c < 0.001Height Z-score− 1.6 ± 2.6− 0.9 ± 1.9a− 4.0 ± 3.8a,c− 1.6 ± 2.0c < 0.001Weight (kg)29.0 ± 16.133.4 ± 17.2a,b22.0 ± 12.2a,c28.4 ± 15.7b,c0.087Weight Z-score− 0.1 ± 1.50.3 ± 1.5a,b− 1.4 ± 1.9a,c− 0.3 ± 1.1b,c < 0.001BMI (kg/m2)18.7 ± 4.018.8 ± 3.719.9 ± 4.8c18.4 ± 3.6c0.154BMI SDS1.15 ± 1.871.20 ± 1.801.23 ± 1.711.08 ± 1.860.880Overweight, n (%)10 (4.9%)7 (8.3%)2 (5.6%)1 (1.2%)0.121Obese, n (%)38 (18.6%)12 (16.7%)11 (30.6%)14 (17.3%)0.109Nonambulatory, n (%)78 (38.2%)14 (14.3%)a,b29 (80.6%)a,c35 (43.2%)b,c < 0.001Number of fractures4.0 (3.0, 7.0)3.0 (2.0, 5.0)a,b10.0 (4.3, 20.0)a,c5.0 (3.8, 6.0)b,c < 0.001Ca (mmol/L)2.46 ± 0.202.47 ± 0.092.48 ± 0.112.43 ± 0.300.427P (mmol/L)1.66 ± 0.201.69 ± 0.201.68 ± 0.211.64 ± 0.190.251ALP (U/L)285.7 ± 103.3302.6 ± 106.2a246.5 ± 84.6a280.4 ± 93.90.018β-CTX (ng/ml)0.86 ± 0.360.91 ± 0.37a0.67 ± 0.32a0.85 ± 0.340.04425OHD (ng/ml)21.2 (13.7, 31.6)21.4 (16.1, 31.5)25.5 (17.2, 39.3)22.3 (15.4, 27.8)0.456PTH (ng/ml)21.2 (13.7, 31.6)22.9 (17.7, 32.8)a17.4 (10.5, 25.6)a19.2 (11.1, 32.7)0.036ALT (U/L)14.0 (11.0, 18.0)14.0 (11.3, 19.0)a12.0 (9.0, 16.0)a,c14.0 (11.0, 19.0)c0.054Cr (μmol/L)35.8 ± 12.338.7 ± 12.3a,b33.1 ± 11.0a34.6 ± 12.6b0.038eGFR (ml/min/1.73m2)173.8 ± 41.2174.2 ± 37.8a157.6 ± 48.2a,c190.7 ± 39.8c0.025FBG (mmol/L)5.07 ± 0.395.00 ± 0.35a5.27 ± 0.41a,c5.04 ± 0.39c0.002Insulin (μIU/mL)9.00 (6.00, 14.50)7.90 (4.30, 13.80)9.00 (7.40, 12.80)10.50 (5.40, 17.90)0.148HOMA-IR2.00 (1.34, 3.38)1.79 (1.03, 3.16)2.08 (1.68, 3.22)2.36 (1.22, 4.03)0.157HOMA-β (%)118.33 (80.00, 187.69)109.23 (66.32, 181.25)111.43 (92.50, 155.56)142.35 (76.47, 250.00)0.099TC (mmol/L)4.21 ± 0.794.14 ± 0.864.11 ± 0.654.31 ± 0.790.365TG (mmol/L)0.83 ± 0.450.82 ± 0.480.80 ± 0.390.85 ± 0.460.848HDL-C (mmol/L)1.04 ± 0.261.03 ± 0.261.07 ± 0.251.03 ± 0.260.795LDL-C (mmol/L)2.23 ± 0.572.19 ± 0.592.12 ± 0.412.33 ± 0.610.170LCN2 (ng/ml)37.65 ± 23.4839.14 ± 23.29a26.23 ± 14.83a,c39.59 ± 23.89c0.007OC (ng/ml)24.15 ± 10.8225.93 ± 10.51a17.84 ± 9.29a,c24.95 ± 11.04c0.001LS BMD (g/cm2)0.467 ± 0.1990.547 ± 0.190a,b0.341 ± 0.170a,c0.448 ± 0.178b,c < 0.001LS BMD Z-score− 2.2 ± 2.1− 1.4 ± 1.8a,b− 3.4 ± 2.1a− 2.6 ± 1.9b < 0.001FN BMD (g/cm2)0.427 ± 0.1880.517 ± 0.190a,b0.285 ± 0.160a,c0.396 ± 0.146b,c < 0.001FN BMD Z-score− 3.7 ± 2.3− 2.7 ± 2.0a,b− 5.3 ± 2.8a,c− 4.2 ± 1.9b,c < 0.001Troch BMD (g/cm2)0.349 ± 0.1940.415 ± 0.204a,b0.268 ± 0.187a0.315 ± 0.163b < 0.001TH BMD (g/cm2)0.471 ± 0.2080.550 ± 0.223a,b0.350 ± 0.186a,c0.433 ± 0.163b,c < 0.001OI osteogenesis imperfecta, BMI body mass index, SDS standard deviation score, Ca calcium, P phosphate, ALP alkaline phosphatase, β-CTX β cross-linked carboxy-terminal telopeptide of type I, 25OHD 25-hydroxyvitamin D, PTH parathyroid hormone, FBG fasting blood glucose, HOMA-IR homeostasis model assessment insulin resistance, HOMA-β homeostasis model assessment islet beta cell function, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, LCN2 lipocalin 2, OC osteocalcin, ALT alanine aminotransferase, Cr creatinine, eGFR estimated glomerular filtration rate, LS lumbar spine, FN femoral neck, Troch trochanter, TH total hip, BMD bone mineral densityBold values indicated that there was a significant difference among three groupsaP < 0.05 for comparison between OI-type I and OI-type III; bP < 0.05 for comparison between OI-type I and OI-type IV; cP < 0.05 for comparison between OI-type III and OI-type IV
Source: Association of LCN2 levels, metabolic abnormalities, and clinical severity of OI patients. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
A total of 204 children with OI and 66 age: and gender-matched healthy children were included.
Source: Abstract.
This was a cross-sectional study conducted in endocrinology department of Peking Union Medical College Hospital (PUMCH) from May 2018 to April 2022.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Correlation of lipocalin 2 and glycolipid metabolism and body composition in a large cohort of children with osteogenesis imperfecta
Cross-sectional study · Journal of Endocrinological Investigation · 2023
Original publication title
Correlation of lipocalin 2 and glycolipid metabolism and body composition in a large cohort of children with osteogenesis imperfecta
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Lipocalin 2 (LCN2) is a newly recognized bone-derived factor that is important in regulation of energy metabolism. We investigated the correlation of serum LCN2 levels and glycolipid metabolism, and body composition in a large cohort of patients with osteogenesis imperfecta (OI).
Source: PurposeAbstract: What methods does the paper describe?
A total of 204 children with OI and 66 age: and gender-matched healthy children were included. Circulating levels of LCN2 and osteocalcin were measured by enzyme-linked immunosorbent assay. Serum levels of fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), and low: and high-density lipoprotein cholesterol (LDL-C, HDL-C) were measured by automated chemical analyzers. The body composition was measured by dual-energy X-ray absorptiometry. Grip strength and timed-up-and-go (TUG) were tested to evaluate the muscle function.
Source: MethodsAbstract: Results
Serum LCN2 levels were 37.65 ± 23.48 ng/ml in OI children, which was significantly lower than those in healthy control (69.18 ± 35.43 ng/ml, P < 0.001). Body mass index (BMI) and serum FBG level were significantly higher and HDL-C levels were lower in OI children than healthy control (all P < 0.01). Grip strength was significantly lower (P < 0.05), and the TUG was significantly longer in OI patients than healthy control (P < 0.05). Serum LCN2 level was negatively correlated to BMI, FBG, HOMA-IR, HOMA-β, total body, and trunk fat mass percentage, and positively correlated to total body and appendicular lean mass percentage (all P < 0.05).
Source: ResultsAbstract: Conclusions
Insulin resistance, hyperglycemia, obesity, and muscle dysfunction are common in OI patients. As a novel osteogenic cytokine, LCN2 deficiency may be relevant to disorders of glucose and lipid metabolism, and dysfunction of muscle in OI patients.
Source: ConclusionsAuthors’ abstract
Purpose
Lipocalin 2 (LCN2) is a newly recognized bone-derived factor that is important in regulation of energy metabolism. We investigated the correlation of serum LCN2 levels and glycolipid metabolism, and body composition in a large cohort of patients with osteogenesis imperfecta (OI).
Methods
A total of 204 children with OI and 66 age: and gender-matched healthy children were included. Circulating levels of LCN2 and osteocalcin were measured by enzyme-linked immunosorbent assay. Serum levels of fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), and low: and high-density lipoprotein cholesterol (LDL-C, HDL-C) were measured by automated chemical analyzers. The body composition was measured by dual-energy X-ray absorptiometry. Grip strength and timed-up-and-go (TUG) were tested to evaluate the muscle function.
Results
Serum LCN2 levels were 37.65 ± 23.48 ng/ml in OI children, which was significantly lower than those in healthy control (69.18 ± 35.43 ng/ml, P < 0.001). Body mass index (BMI) and serum FBG level were significantly higher and HDL-C levels were lower in OI children than healthy control (all P < 0.01). Grip strength was significantly lower (P < 0.05), and the TUG was significantly longer in OI patients than healthy control (P < 0.05). Serum LCN2 level was negatively correlated to BMI, FBG, HOMA-IR, HOMA-β, total body, and trunk fat mass percentage, and positively correlated to total body and appendicular lean mass percentage (all P < 0.05).
Conclusions
Insulin resistance, hyperglycemia, obesity, and muscle dysfunction are common in OI patients. As a novel osteogenic cytokine, LCN2 deficiency may be relevant to disorders of glucose and lipid metabolism, and dysfunction of muscle in OI patients.
Supplementary Information
The online version contains supplementary material available at 10.1007/s40618-023-02121-4.
Publication and source details
Original title: Correlation of lipocalin 2 and glycolipid metabolism and body composition in a large cohort of children with osteogenesis imperfecta
W.-b. Zheng; J. Hu; L. Sun; J.-y. Liu; Q. Zhang; O. Wang; Y. Jiang; W.-b. Xia; X.-p. Xing; M. Li
Journal of Endocrinological Investigation · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.National Key R&D Program of China2018YFA0800801Li M. National Key R&D Program of China2021YFC2501704Li M. CAMS Innovation Fund for Medical Sciences (CIFMS)2021-I2M-C&T-B-0072021-I2M-1-051Li M. http://dx.doi.org/10.13039/501100001809National Natural Science Foundation of China8187366882070908Li M. Beijing Natural Science Foundation7202153Li M.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T18:10:18.654445+00:00
DOI: 10.1007/s40618-023-02121-4 · PMC10776749